JP2008520706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520706A5 JP2008520706A5 JP2007543270A JP2007543270A JP2008520706A5 JP 2008520706 A5 JP2008520706 A5 JP 2008520706A5 JP 2007543270 A JP2007543270 A JP 2007543270A JP 2007543270 A JP2007543270 A JP 2007543270A JP 2008520706 A5 JP2008520706 A5 JP 2008520706A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- formula
- hydrogen
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000006239 protecting group Chemical group 0.000 claims 8
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000037067 skin hydration Effects 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63018104P | 2004-11-22 | 2004-11-22 | |
| PCT/US2005/041821 WO2006057902A2 (en) | 2004-11-22 | 2005-11-18 | 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520706A JP2008520706A (ja) | 2008-06-19 |
| JP2008520706A5 true JP2008520706A5 (enExample) | 2009-01-15 |
Family
ID=36216925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543270A Ceased JP2008520706A (ja) | 2004-11-22 | 2005-11-18 | ２α−メチル−１９−ノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8399438B2 (enExample) |
| EP (1) | EP1838667A2 (enExample) |
| JP (1) | JP2008520706A (enExample) |
| AU (1) | AU2005309807B2 (enExample) |
| CA (1) | CA2588412A1 (enExample) |
| MX (1) | MX2007006545A (enExample) |
| NZ (1) | NZ555279A (enExample) |
| WO (1) | WO2006057902A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ555283A (en) * | 2004-11-22 | 2010-12-24 | Wisconsin Alumni Res Found | 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses |
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666634A (en) * | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
| JP2898882B2 (ja) * | 1993-04-05 | 1999-06-02 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物 |
| DE69606680T2 (de) * | 1995-10-30 | 2000-08-17 | F. Hoffmann-La Roche Ag, Basel | 1-Alpha, 26-dihydroxy-D-homo-vitamin D3 |
| US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US5939406A (en) * | 1997-07-21 | 1999-08-17 | Wisconsin Alumni Research Foundation | 18-substituted-19-nor-vitamin D compounds |
| ES2309069T3 (es) * | 2000-05-31 | 2008-12-16 | Wisconsin Alumni Research Foundation | Compuestos de 2-etil y 2-etiliden-19-nor-vitamina d. |
| BR0113703A (pt) * | 2000-09-08 | 2003-07-22 | Wisconsin Alumni Researcg Foun | Compostos e métodos de tratamento de psorìase, leucemia, câncer do cólon, do seio ou da próstata, osteodistrofia renal, de doenças auto-imune, inflamatória e de condição de pele |
| US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| US6566352B1 (en) * | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| CA2544502A1 (en) | 2003-11-25 | 2005-06-09 | Wisconsin Alumni Research Foundation | Vitamin d analogs for obesity prevention and treatment |
| ATE508750T1 (de) * | 2005-12-12 | 2011-05-15 | Women And Infants Hospital Of Rhode Island | Derivate von vitamin d und ihre verwendung in der therapie |
-
2005
- 2005-11-18 CA CA002588412A patent/CA2588412A1/en not_active Abandoned
- 2005-11-18 US US11/283,261 patent/US8399438B2/en not_active Expired - Fee Related
- 2005-11-18 WO PCT/US2005/041821 patent/WO2006057902A2/en not_active Ceased
- 2005-11-18 MX MX2007006545A patent/MX2007006545A/es unknown
- 2005-11-18 AU AU2005309807A patent/AU2005309807B2/en not_active Ceased
- 2005-11-18 JP JP2007543270A patent/JP2008520706A/ja not_active Ceased
- 2005-11-18 EP EP05851806A patent/EP1838667A2/en not_active Withdrawn
- 2005-11-18 NZ NZ555279A patent/NZ555279A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520689A5 (enExample) | ||
| JP2008520703A5 (enExample) | ||
| JP2008520691A5 (enExample) | ||
| JP2005529878A5 (enExample) | ||
| JP2008520705A5 (enExample) | ||
| JP2010504995A5 (enExample) | ||
| JP2008200039A5 (enExample) | ||
| JP2006524669A5 (enExample) | ||
| WO2006004658A3 (en) | Furanopyrimidines | |
| CN103443085A (zh) | 喹唑啉二酮及其应用 | |
| JP2008508303A5 (enExample) | ||
| JP2006182786A5 (enExample) | ||
| JP2006508107A5 (enExample) | ||
| JP2004531544A5 (enExample) | ||
| JP2008520704A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| WO2005106492A3 (en) | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3) | |
| JP2008520716A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| CA2420026A1 (en) | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications | |
| JP2011527695A5 (enExample) | ||
| JP2011527699A5 (enExample) | ||
| JP2011527696A5 (enExample) | ||
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| JP2010504994A5 (enExample) |